CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Germline alterations in many genes coding for proteins regulating DNA repair and DNA damage response (DDR) to DNA double-strand breaks (DDSB) have been recognized as pathogenic factors in hereditary cancer predisposition. The ATM-CHEK2-p53 axis has been documented as a backbone for DDR and hypothesized as a barrier against cancer initiation. However, although CHK2 kinase coded by the CHEK2 gene expedites the DDR signal, its function in activation of p53-dependent cell cycle arrest is dispensable. CHEK2 mutations rank among the most frequent germline alterations revealed by germline genetic testing for various hereditary cancer predispositions, but their interpretation is not trivial. From the perspective of interpretation of germline CHEK2 variants, we review the current knowledge related to the structure of the CHEK2 gene, the function of CHK2 kinase, and the clinical significance of CHEK2 germline mutations in patients with hereditary breast, prostate, kidney, thyroid, and colon cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“The competence of the ATM-CHK2-p53 signaling cascade has been hypothesized as a barrier preventing early tumorigenesis [17], inducing cell cycle blockade, apoptosis, or senescence in transformed cells [18].”
BackgroundInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680
Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997) · Science · doi:10.1126/science.277.5331.1501 · Cited by 1,341 · cited 1×
“The interaction with 14-3-3 proteins displaces CDC25C from binding and the dephosphorylation of a CDK1-cyclin B complex, required for its activation before mitotic entry [16,88].”
BackgroundThe Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222 · cited 1×
“The inhibition of CDC25 phosphatases by phosphorylation ensures rapid but transient checkpoint activation, while the activation of p53 is required for longer cell cycle arrest, the induction of senescence, or apoptosis [87].”
BackgroundThe CHEK2-Breast Cancer Consortium (2002) · Nature Genetics · doi:10.1038/ng879 · Cited by 1,104
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis
Falck, J., Mailand, N., Syljuåsen, R. G., Bartek, J., & Lukas, J. (2001) · Nature · doi:10.1038/35071124 · Cited by 1,085
WINPEPI updated: computer programs for epidemiologists, and their teaching potential
Abramson, J. H. (2011) · Epidemiologic Perspectives & Innovations · doi:10.1186/1742-5573-8-1 · Cited by 844 · cited 1×
“* Calculated using WINPEPI [208]; ** CHEK2 = an analysis of the entire coding sequence (dominantly without CNV); otherwise specified if certain CHEK2 variants were genotyped.”
MethodDNA damage signalling guards against activated oncogenes and tumour progression
Bartek, J., Bartkova, J., & Lukas, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210881 · Cited by 521
CHK2 kinase in the DNA damage response and beyond
Zannini, L., Delia, D., & Buscemi, G. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju045 · Cited by 455 · cited 3×
“t that w re comprehensively reviewed by Z nini and colleagues [69].”
BackgroundInfluentialKurian, A. W., Ward, K. C., Howlader, N., Deapen, D., Hamilton, A. S., Mariotto, A., Miller, D., Penberthy, L. S., & Katz, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01854 · Cited by 387 · cited 1×
“Kurian and colleagues collected data from germline testing in 5900 breast and 937 ovarian cancer patients from California and Georgia [128].”
BackgroundThe Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer
Alves-Fernandes, D. K., & Jasiulionis, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133153 · Cited by 385
Chk2 Phosphorylation of BRCA1 Regulates DNA Double-Strand Break Repair
Zhang, J., Willers, H., Feng, Z., Ghosh, J. C., Kim, S., Weaver, D. T., Chung, J. H., Powell, S. N., & Xia, F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.708-718.2004 · Cited by 323 · cited 2×
“In response to ionizing radiation, CHK2 phosphorylates breast cancer susceptibility protein 1 (BRCA1) at S988, which is believed to modulate the BRCA1 function in DNA repairs towards a homologous recombination (HR) repair instead of non-homologous end joining (NHEJ) [92,93].”
BackgroundATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage
Chen, L., Gilkes, D. M., Pan, Y., Lane, W. S., & Chen, J. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600812 · Cited by 260 · cited 2×
“Besides, CHK2 phosphorylates MDM4 on S342 and S367 in vivo [76], possibly impacting the”
BackgroundCrosstalk between chromatin state and DNA damage response in cellular senescence and cancer.
Sulli, G., Di Micco, R., & di Fagagna, F. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3344 · Cited by 238
Yurgelun, M. B., Chittenden, A. B., Morales-Oyarvide, V., Rubinson, D. A., Dunne, R. F., Kozak, M. M., Qian, Z. R., Welch, M. W., Brais, L. K., Da Silva, A., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-018-0009-5 · Cited by 217
RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability
Heikkinen, K. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi360 · Cited by 208 · cited 1×
“Phosphorylated S516 is more accessible for dephosphorylation by other phosphatases, including PP2Cα [57].”
BackgroundAge- and Tumor Subtype–Specific Breast Cancer Risk Estimates for CH EK 2 *1100delC Carriers
Schmidt, M. K., Hogervorst, F., van Hien, R., Cornelissen, S., Broeks, A., Adank, M. A., Meijers, H., Waisfisz, Q., Hollestelle, A., Schutte, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.5844 · Cited by 173 · cited 3×
“Although ER+ tumors tend to have a better prognosis in unselected breast cancer patients, ER+ tumors in CHEK2 mutation carriers were associated with worse breast cancer-specific survival [155,184].”
BackgroundThe Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer Cells
Jallepalli, P. V., Lengauer, C., Vogelstein, B., & Bunz, F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213159200 · Cited by 154 · cited 1×
“In agreement with this, no checkpoint defect was observed in HCT116 cells lacking CHK2 and thus the impact of CHK2 on the p53 pathway remains unclear [33,81].”
BackgroundGallagher, S., Hughes, E., Wagner, S., Tshiaba, P., Rosenthal, E., Roa, B. B., Kurian, A. W., Domchek, S. M., Garber, J., Lancaster, J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8501 · Cited by 137
Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients
Hu, C., Hart, S. N., Bamlet, W. R., Moore, R. M., Nandakumar, K., Eckloff, B. W., Lee, Y. K., Petersen, G. M., McWilliams, R. R., & Couch, F. J. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0455 · Cited by 137
Mutation analysis of the CHK2gene in families with hereditary breast cancer
Allinen, M., Huusko, P., Mäntyniemi, S., Launonen, V, & Winqvist, R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1858 · Cited by 85
Cited by
Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches
Liu, F., Chen, J., Li, K., Li, H., Zhu, Y., Zhai, Y., Lu, B., Fan, Y., Liu, Z., Chen, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02046-3 · Cited by 326
CHEK2 knockout is a therapeutic target for TP53-mutated hepatocellular carcinoma
Chen, Y., Zhu, Z., Wu, X., Li, H., Guan, W., & Ren, H. (2024) · Cell Death Discovery · doi:10.1038/s41420-023-01777-4 · Cited by 6
Metadata
- Authors
- Stolarova, L., Kleiblova, P., Janatova, M., Soukupova, J., Zemankova, P., Macurek, L., & Kleibl, Z.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2020-12-12
- Volume
- 9
- Issue
- 12
- Pages
- 2675
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W3110887898
- Cited by
- 190
- References
- 23
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.